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BACKGROUND: Interleukin-6 (IL-6) binds both the membrane and soluble forms of the IL-6 receptor (sIL-6R), which induces a complex
with gp130, and proliferation of tumour cells. The aim of this study is to clarify the relationship between tumoral sIL-6R expression
and disease progression in colorectal cancer patients.
METHODS: We measured tissue concentrations of sIL-6R in tumour and normal mucosa from 161 colorectal cancer patients
undergoing surgery, and in supernatants from colon cancer cell lines. The expression of IL-6, IL-6R and gp130 was evaluated by
immunohistochemical analysis.
RESULTS: Loss of tumour expression of sIL-6R as defined by sIL-6R Ca/N ratio o1.0 was significantly associated with factors reflecting
disease progression, and was an independent prognostic factor not only in all the patients in this study, but also in the patients with
curative intent. Colon cancer cell lines produced sIL-6R in vitro, and the production of sIL-6R in cancer cell lines was stimulated by
cytokine stimulation. Immunohistochemistry revealed that loss of tumour expression of sIL-6R was significantly inversely correlated
with intense IL-6 expression in the cytoplasm of cancer cells. In addition, tumoral IL-1b expression was significantly correlated with
sIL-6R expression.
CONCLUSION: Loss of tumour expression of sIL-6R is associated with colorectal cancer disease progression.
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The inflammatory response has been shown to be intimately
involved in colorectal cancer progression and correlates with a
poor outcome in patients undergoing resection for colorectal
cancer. A mechanistic link between inflammation and colorectal
cancer progression is supported by the finding that precursor
lesions of colorectal cancer often show inflammatory histological
features (Higaki et al, 1999). In addition, the inflammatory
response promotes carcinogenesis by damaging DNA (Jaiswal
et al, 2000), stimulating angiogenesis and cell proliferation, and
inhibiting apoptosis (Jackson et al, 1997). These recent reports
suggest that inflammation is intimately involved in carcinogenesis
and cancer progression in colorectal cancer.
Interleukin-6 (IL-6) is a pleiotropic cytokine that has a key role
in the induction and maintenance of the inflammatory response
with many ascribed effects, including immunoregulation, angio-
genesis, and osteoclast activation (Taga and Kinoshita, 1997; Lauta,
2003; Sohara et al, 2005; Hong et al, 2007). Several human tumour
cell lines are known to produce IL-6 (Kawano et al, 1988;
Miki et al, 1989; Meir et al, 1990; Siegall et al, 1990; Watson et al,
1990; Lee et al, 1992; Ohsaki et al, 1992; Takizawa et al, 1993;
Oka et al, 1996). Clinically, serum IL-6 levels increase in colorectal
cancer patients relative to healthy controls, and is correlated with
tumour size, suggesting its potential as a prognostic marker of
tumour progression (Galizia et al, 2002; Chung and Chang, 2003).
Experimentally, IL-6 has been implicated as a promoter of cancer
growth by enhancing colony formation of human colon carcinoma
cells in a dose-dependent manner in vitro (Schneider et al, 2000).
These data suggest that IL-6 has a pivotal role in the progression of
colorectal cancer.
Interleukin-6 exerts its activity on target cells by binding to the
ligand-specific receptor IL-6R, which exists aseither a membrane-
bound or a soluble form (sIL-6R). Classic signalling of IL-6
involves IL-6 binding to target cells bearing the membrane-
associated IL-6R. Alternatively, IL-6 can activate cells lacking the
membrane-associated IL-6R when IL-6 binds the naturally
occurring sIL-6R in a process called IL-6 trans-signalling (Jones
et al, 2001), whereby IL-6/sIL-6R complexes activate the gp130
signalling receptor on the cell surface. Soluble forms of the IL-6
receptor is released into the circulation by T cells, macrophages,
and granulocytes by proteolytic cleavage from the cell surface
(Mullberg et al, 1993), or by differential messenger RNA splicing
(Horiuchi et al, 1994).
Although most soluble receptors function as functional antago-
nists for their specific cytokine, sIL-6R shows agonistic activity
(Rose-John and Heinrich, 1994). Given the inflammatory proper-
ties of IL-6, sIL-6R could emerge as an important inflammatory Received 17 March 2010; revised 30 June 2010; accepted 4 July 2010
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smediator at different stages of colon cancer pathogenesis through
IL-6 signalling in colorectal cancer cells. However, no study has yet
clarified the relationship between the expression of intra-tumoral
sIL-6R and cancer progression in colorectal cancer patients.
In this report we evaluated the relationship between intra-
tumoral expression of sIL-6R and disease progression in patients
with colorectal cancer. We also examined the significance of IL-6
trans-signalling in the cancer microenvironment with colorectal
cancer progression.
PATIENTS AND METHODS
Among the 243 consecutive patients who underwent surgery
for colorectal cancer from January 1996 to January 2003 at Mie
University Hospital, Japan, 109 patients who were followed up over
a 5-year period for evidence of recurrence, and 52 patients who
died of primary or recurrent disease within 5 years of the follow-up
period were enrolled in this study. Another factor for inclusion in
this study was the retention of excellent cancer and normal tissue
samples. Out of the 161 patients, 104 were male. The mean age
was 64.6 years (range 37–86 years). No perioperative mortalities
were observed among these patients. No patients had received
chemotherapy or radiation therapy before surgery.
The location of the tumours and distant metastases were deter-
mined by barium enema, colonoscopy, computed tomography
(CT), and magnetic resonance imaging (MRI). The primary lesion
was located in the rectum in 70 patients, the sigmoid colon in
48 patients, the ascending colon in 30 patients, the transverse
colon in 8 patients, and the descending colon in 5 patients. In all,
26 patients were diagnosed with synchronous liver metastasis, and
3 patients with both liver metastasis and peritoneal dissemination.
Resection of the primary tumour was carried out in all patients,
and simultaneous partial hepatectomy for liver metastasis was
carried out in 12 patients. In total, 12 patients had poorly differen-
tiated adenocarcinomas, while 149 patients had well differentiated
or moderately differentiated adenocarcinomas. All patients were
classified according to the Union Internationale Contre le Cancer
(UICC) classification system, based on resected specimens. There
were 38 patients with UICC stage I (T1-2N0M0), 36 patients
with UICC stage II (T3-4N0M0), 52 patients with UICC stage III
(TXN1-2M0), and 35 patients with UICC stage IV (TXNXM1)
disease. Stage III and IV patients received fluorouracil-based
chemotherapy, whereas stage I and II patients received no post-
operative adjuvant therapy. Patients were observed at 3-month
intervals for 24 months after completion of surgery, followed by
every 6 months for 3 years, and then yearly. History was taken and
a physical examination was carried out at each visit, and chest
X-ray, colonoscopy, and CT were carried out annually. The median
follow-up time was 63.2 months (mean: 59.9±38.7). Among the
161 patients studied, 56 patients died because of primary or
recurrent disease. The clinicopathological parameters studied
for their possible prognostic value were as follows: T classification,
vessel involvement, lymphatic invasion, lymph node metastases,
and distant metastasis.
Fresh surgical specimens of primary colorectal carcinoma were
taken from the distant stump of the resected specimens under
sterile conditions, and were placed immediately in liquid nitrogen
and stored at  801C until assayed.
Tissue concentrations of sIL-6R and IL-1b
In all, 322 specimens (161 cancer and 161 normal colorectal
mucosa) were prepared for analysis of tissue expression of sIL-6R
and IL-1b. These samples were thawed, quickly weighed, and
placed in 5ml of phosphate-buffered saline (PBS). The tissues
were homogenised on ice in 1ml extraction buffer per 100mg
wet weight of tissue using a motor-driven Teflon pestle for 5min.
The tissue extract obtained after centrifugation at 12000r.p.m. for
15min at 41C was placed in a 200-ml vial, and stored at  801C. The
concentrations of cytokines in these tissues were measured in the
supernatant using commercially available enzyme-linked immuno-
sorbent assay (ELISA) kits for both sIL-6R and IL-1b (BioSource
International, Camarillo, CA, USA). Protein concentrations were
measured using a BCA Protein Assay Kit (Pierce Chemical,
Rockford, IL, USA). Tissue concentrations were expressed as pg
sIL-6R or IL-1b per mg total protein. Informed consent was
obtained from each subject.
Immunohistochemical analysis
In total, 52 patients were randomly selected for immunohisto-
chemical analysis. Out of these, 31 patients were male. The mean
age was 62.7 years (range 37–81 years). There were 9 patients with
UICC stage I, 12 patients with UICC stage II, 16 patients with UICC
stage III, and 15 patients with UICC stage IV disease. The median
follow-up time was 63.0 months (mean: 59.9±41.0). Out of the
52 patients, 19 patients died because of primary or recurrent
disease. Paraffin block specimens were cut into 5-mm sections, and
attached to glass slides with melted wax at 651C. The sections then
were dewaxed, hydrated, and incubated in 3% hydrogen peroxide
for 30min. The sections were washed in cold tap water, heated
in a microwave oven, and washed three times in PBS (pH 7.4)
for 5min. After washing with PBS, sections were incubated
with primary antibodies overnight at 41C. Non-specific binding
was blocked by incubation with blocking solution for 1h at
room temperature. The sections were incubated with appro-
priate antibody overnight at 41C: anti-IL-6 (1:200; Santa Cruz
Biotechnology, Santa Cruz, CA, USA), anti-IL-6Ra (1:200;
Santa Cruz Biotechnology), and anti-gp130 (1:200; Santa Cruz
Biotechnology). The sections were washed and incubated for
30min at room temperature with an appropriate biotinylated
IgG diluted in PBS. The sections were then incubated with avidin/
biotin complex (ABC) reagent for 3h at room temperature. The
colour was developed for 90s using a Vector DAB substrate kit and
counterstained with Meyer’s haematoxylin (Vector Laboratories,
Burlingame, CA, USA). In addition, concentrations of IL-6 in tissue
extracts from these groups (52 cancer and 52 normal colorectal
mucosa) were measured using a commercially available ELISA kit
(BioSource International). Tissue concentrations were expressed
as pg IL-6 per mg total protein.
Evaluation of degree of antibody reactivity
The specificity of the immunoreaction was verified by staining
known positive and negative control tissue sections. The degree of
anti-IL-6, anti-IL-6Ra, and anti-gp130 reactivity in each tissue
section was scored according to the percentage of stained cancer
cells and cancer stromal tissues in the section. In this study,
cancer cells and cancer stromal tissues with more than 50% stained
cells were defined as ‘positive’, and others (o50%) as ‘reduced’,
as described previously (Komatsu et al, 2000). The slides were
evaluated three times by three independent investigators, who
were blinded to the nature of the specimens and antibodies used.
Cell culture conditions
The human colon cancer cell line HT-29 was obtained from the
Cell Resource Center for Biomedical Research, Institute of
Development, Aging and Cancer, Tohoku University, Japan. RPMI
1640 medium was purchased from Sigma (St Louis, MO, USA).
Fetal bovine serum (FBS) and non-essential amino acids (NEAAs)
were purchased from GIBCO-BRL (Grand Island, NY, USA).
Recombinant human IL-1b was purchased from Peprotech House
(London, UK). Recombinant human IL-1 receptor antagonist
(IL-1RA) was purchased from R&D Systems Inc. (Minneapolis, MN,
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sUSA). All cells were maintained in RPMI 1640 medium containing
10% FBS, and prepared to a final concentration of 1 10
5cellsml
 1,
and cultured in six-well plates. After 24h starvation in serum-free
medium, serum-free medium with or without IL-1b (10ngml
 1)
and IL-1RA (100ngml
 1) were added. The conditioned medium
(CM) was harvested at 0, 1, 3, 6, 12, and 24h and stored at  801C.
Supernatant concentrations of sIL-6R and soluble gp130 (sgp130)
(Quantikine, Minneapolis, MN, USA) were measured by ELISA.
Total RNA extraction and semi-quantitative RT–PCR
analysis
To clarify that IL-1b enhances IL-6R splice variant expression
and/or the shedding of the membrane-bound form of IL-6R, we
carried out semi-quantitative RT–PCR analysis to detect both
IL-6R and sIL-6R, which lack the transmembrane (TM) domain
(Horiuchi et al, 1994). Cells were maintained in RPMI 1640
medium containing 10% FBS, and seeded at a final concentration
of 1 10
5cellsml
 1, and cultured in six-well plates. After 24h
starvation in serum-free medium, serum-free medium with or
without IL-1b (10ngml
 1) and IL-1RA (100ngml
 1) were added.
Cells were collected at 0, 6, and 12h as follows: tumour cells were
washed with PBS and harvested with trypsin. Following this, total
RNA was extracted using an RNeasy Midi kit (Qiagen Inc.,
Chatsworth, CA, USA) according to the manufacturer’s instruc-
tions. Primers used for the PCR of IL-6R were as follows: either
IL-6R or sIL-6R primers (sense, 50-ACGCCTTGGACAGAATCCA-30,
and antisense, 30-TGGCTCGAGGTATTGTCAGA-50)a sd e s c r i b e d
previously (Horiuchi et al, 1994). Primers for b-actin were designed
with Primer3 software (Biology Workbench Version 3.2, San Diego
Supercomputer Center, at the University of California, San Diego,
CA, USA). Sequences were as follows: b-actin (sense, 50-ACAG
AGCCTCGCCTTTGC-30, and antisense, 30-GCGGCGATATCAT
CATCC-50). Optimal cycling parameters in the linear phase of
amplification consisted of 35 cycles of 1min denaturation at 911C,
1min annealing at 611C, and 1min elongation at 721C for selected
genes. Control PCR (35 cycles) was also performed for b-actin as a
standard for sample normalisation. Amplified products were
separated electrophoretically, visualised, and photographed under
UV light after ethidium bromide staining, and quantified by CA
Analyzer version 2.0 (ATTO Corporation, Tokyo, Japan).
Statistical analysis
Statistical analysis was carried out using Medcalc 7.2 for Windows
(Broekstraat 52, 9030, Mariakerke, Belgium). Results are expressed
as mean±s.d. Mann–Whitney U-tests were used to evaluate
differences between unpaired observations. Contingency tables
among the tissue concentration ratio and clinicopathological
factors were analysed using Fisher’s exact probability test or
w
2-analysis. The Wilcoxon rank correlation test was conducted
for statistical analysis. Actuarial survival curves were obtained
using the Kaplan–Meier method, and comparisons were made
using log-rank tests. Prognostic factors were examined by
univariate and multivariate analyses (Cox proportional hazards
model). Two-sided P-values o0.05 were considered to be
statistically significant.
RESULTS
Loss of tumoral sIL-6R expression associates with
clinicopathological scores
The concentrations of sIL-6R in cancer tissues ranged from 218.9
to 24648pg per mg protein, with a mean level of 1863.5±2474.3pg
per mg protein. The concentrations of sIL-6R in normal mucosa
ranged from 108.3 to 19995pg per mg protein, with a mean level
of 1808.8±2146.1pg per mg protein. The ratio between the
concentrations of sIL-6R in cancer tissue and normal mucosa
(sIL-6R Ca/N ratio: cancer tissue sIL-6R concentration divided by
normal mucosa sIL-6R concentration) ranged from 0.096 to 6.631
with a mean value of 1.262±1.156. The ROC curve analysis showed
that the best cut-off value was 1.021 (sensitivity 73.1%, specificity
56.9%). Thus, the cut-off value was set at 1.0 and was used to
classify the tumoral expression of sIL-6 as over-expression or
under-expression compared with normal mucosa. Patients with a
sIL-6R Ca/N ratio of o1.0 were considered to have lost tumoral
expression of sIL-6R (n¼84), whereas those with values 1.0 were
considered to have high tumoral expression of sIL-6R (n¼77).
Loss of tumoral expression was found in 52% of the patients, and
in 47% of patients undergoing surgery with curative intent.
The mean level of the sIL-6R Ca/N expression ratios in stage I
patients was significantly higher than those in stage II, III or IV
patients (Figure 1A). Table 1 shows the relationship between the
sIL-6R Ca/N expression ratio and clinicopathological findings.
Loss of tumoral sIL-6R expression was associated with factors
showing disease progression, such as T classification, the presence
of distant metastasis, and the progression of UICC classification.
In addition, the mean level of the sIL-6R Ca/N expression ratio in
the T2 patients was significantly higher than the levels in T3 or
T4 patients (Figure 1B).
Loss of tumoral sIL-6R expression correlates with poorer
prognosis
Figure 2A shows the actual survival curves for all colorectal
carcinoma patients, subdivided by their sIL-6R Ca/N expres-
sion ratio. Patients who lost tumoral sIL-6R expression had
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Figure 1 (A) Scattergram of the sIL-6R Ca/N expression ratios with
UICC classification in 161 colorectal cancer patients. (B) Scattergram of the
sIL-6R Ca/N expression ratios with T classification in 161 colorectal cancer
patients.
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ssignificantly poorer prognoses than those with higher tumoral
sIL-6R expression (log-rank test, P¼0.0003). Figure 2B shows
the actual survival curves for UICC stage I, II, and III patients
undergoing potentially curative surgery. The curative intent
patients who lost tumoral sIL-6R expression also had signi-
ficantly poorer prognoses than those with higher tumoral
sIL-6R expression (log-rank test, P¼0.0174). Table 2a reveals
the resulting risk ratios and 95% confidence intervals (95% CIs)
calculated by Cox proportional hazards analysis in all colorectal
cancer patients. In this analysis, hepatic metastasis and loss of
tumoral sIL-6R expression were independent risk factors for a
poor prognosis. Cox proportional hazards analysis in UICC stage I,
II, and III patients similarly showed that loss of tumoral sIL-6R
expression was an independent risk factor for a poor prognosis
(Table 2b).
Interleukin-6-expression is correlated with a poorer
prognosis for colorectal cancer patients
Figure 3A–F shows the results of immunohistochemical staining
for IL-6, IL-6R, and gp130 in colorectal cancer tissue. Each protein
was intensely expressed within the cancer cells rather than in the
cancer stroma. Although IL-6 was expressed in the cytoplasm of
the cancer cells, IL-6R was expressed in tumour cell membranes. In
addition, gp130 was expressed both in the cytoplasm’s cancer cell’s
and on membranes.Interleukin-6R and gp130 expression in
colorectal cancer patients did not show a significant correlation
with prognosis (data not shown), whereas the patients with
positive IL-6 expression in the cytoplasm of cancer cells had
significantly poorer prognoses than those with reduced IL-6
expression (Figure 3G; log-rank test, P¼0.035). Figure 3H and I
show typical examples of IL-6 staining at different stages of
disease. In addition, sIL-6R Ca/N expression ratios in patients
whose cancer cells’ cytoplasm were IL-6 immunoreactive were
significantly lower than the ratios in patients with reduced
cytoplasmic IL-6 immunoreactivity in cancer cells (0.78±0.41 vs
1.56±1.21; P¼0.0015) (Table 3a). Table 3b shows the quantifica-
tion of IL-6 immunoreactivity by ELISA, and the data showed that
IL-6 immunoreactivity in cancer cells reflected increased IL-6 Ca/N
ratios. In contrast, there was no significant relationship between
sIL-6R Ca/N expression ratios and IL-6R or gp130 immuno-
reactivity in the tumour cell membrane.
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Figure 2 (A) Kaplan–Meier data of the actual 5-year survival rates of all patients, according to sIL-6R Ca/N expression ratios. (B) Kaplan–Meier data of
the actual 5-year survival rates of UICC stage I, II and III patients undergoing potentially curative surgery except synchronous distant metastasis according to
sIL-6R Ca/N expression ratios.
Table 1 Relationships between cancer/normal tissue ratio of sIL-6R and
clinicopathological factors in 161 colorectal patients
sIL-6R expression Ca/N ratio
Variable n HighX1.0 (n¼77) Lowo1.0 (n¼84) P
Gender
Male 104 51 53 0.74
Female 57 26 31
Age (years)
o66 77 37 40 40.99
X66 84 40 44
Pathological T category
11 5 7 8 0.0062*
23 2 2 4 8
39 9 4 1 5 8
41 5 5 1 0
Vessel involvement
+ 87 46 41 0.21
  74 31 43
Lymphatic vessel involvement
+ 145 70 75 0.80
  16 7 9
Lymph node metastasis
N0 84 45 39 0.16
N1 77 32 45
Distant metastasis
M0 126 68 58 0.0131*
M1 35 9 26
UICC stage classification
13 8 2 4 1 4 0.0129*
23 6 1 7 1 9
35 2 2 7 2 5
43 5 9 2 6
Abbreviations: sIL-6R¼soluble forms of the interleukin-6 receptor; sIL-6R expression
Ca/N ratio¼ratio between the concentrations of sIL-6R in cancer tissue and normal
mucosa; UICC¼Union Internationale Contre le Cancer. *Po0.05.
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sSoluble form of IL-6R is secreted by colon cancer cell line
itself
In order to clarify whether a loss of sIL-6R in cancer tissue was due
to a primary deficiency or because of increased consumption, and
to evaluate the complexity of the IL-6 system, we measured sIL-6R
and sgp130 protein levels in the supernatants of HT-29 cells at
various time points, with or without IL-1b and IL-1RA stimulation.
Soluble form of IL-6R was secreted from the colon cancer cell line
itself, and sIL-6R secretion was upregulated by IL-1b stimulation.
In addition, IL-1RA suppressed the IL-1b-induced enhanced
sIL-6R secretion in a time-dependent manner (Figure 4A). The
expression of sgp130 also showed the same patterns as those of
sIL-6R (Figure 4B).
The mechanism by which sIL-6R production increases
following cytokine stimulation
We sought to determine whether IL-1b-mediated stimulation
of sIL-6R was due to increased expression of IL-6R splice variants
and/or the shedding of the membrane-bound form of IL-6R.
Thus, we used semi-quantitative RT–PCR analysis to detect
both IL-6R and spliced sIL-6R, which lacks the TM domain
(Horiuchi et al, 1994). After 6 and 12h, IL-1b stimulation
enhanced both IL-6R splice variant expression and the shedding
of the membrane-bound form of IL-6R, compared with those
without stimulation (Figure 5). In addition, during IL-1b stimula-
tion, IL-1RA inhibited sIL-6R expression by both sIL-6R genera-
tion pathways.
Relationship between tumoral expression of sIL-6R
and IL-1b
The concentrations of IL-1b in cancer tissues ranged from 0.845 to
757pg per mg protein, with a mean level of 37.8±80.2pg per mg
protein. The concentrations of IL-1b in normal mucosa ranged
from 0.38 to 79.4pg per mg protein, with a mean level of
8.69±10.4pg per mg protein. The ratio between the concentra-
tions of IL-1b in cancer tissue and normal mucosa (IL-1b Ca/N
ratio: cancer tissue IL-1b concentration divided by normal mucosa
IL-1b concentration) ranged from 0.86 to 116 with a mean value of
6.75±10.8. The tumoral IL-1b Ca/N expression ratio was positively
correlated with sIL-6R Ca/N expression ratio (Wilcoxon Signed-
rank test, Po0.001) (Figure 6).
DISCUSSION
This study is the first report showing a relationship between
increased loss of sIL-6R expression in colorectal cancer and
disease progression. Many studies have suggested that IL-6 signal
transduction is intimately involved in cancer progression (Becker
et al, 2005; Scheller et al, 2006). Several human tumour cell lines
have been reported to produce IL-6 (Kawano et al, 1988; Miki et al,
1989; Meir et al, 1990; Siegall et al, 1990; Watson et al, 1990; Lee
et al, 1992; Ohsaki et al, 1992; Takizawa et al, 1993; Oka et al,
1996), and an IL-6/IL-6R autocrine loop has been described in
several tumours, including oesophageal carcinoma (Oka et al,
1996), multiple myeloma (Kawano et al, 1988), renal cell
carcinoma (Miki et al, 1989), and colorectal cancer (Kinoshita
et al, 1999). Recently, Grivennikov et al (2009) showed that the
IL-6–Stat3 cascade is an important regulator of the proliferation
and survival of tumour-initiating intestinal epithelial cells. Bollrath
et al (2009) reported that gp130-mediated Stat3 activation has the
capacity to regulate IL-6-dependent intestinal epithelial cell
survival. It also promotes progression through G1 and G2/M cell
cycle phases. Thus, it represents a tumour cell-autonomous
mechanism that bridges chronic inflammation to tumour promo-
tion. These reports suggest that IL-6 produced by the tumour cells
functions as a growth factor that interacts with specific receptors
on the tumour cell surface to induce proliferation or prolongation
of survival by the tumour cells.
However, recent reports highlighted the intimate involve-
ment between cancer progression and IL-6 trans-signaling through
sIL-6R, rather than the classical IL-6 signalling pathway through
IL-6R. Gaillard et al (1999) reported that sIL-6R has a high affinity
for IL-6, and forms a complex with about 70% of secreted IL-6
in the blood, which enhances the biological effect of released
IL-6 (Kovacs, 2001). Becker et al (2004) also reported that IL-6
signalling required tumour cell-derived soluble IL-6R rather than
IL-6R, and that suppression of TGF-b-dependent IL-6 trans-
signaling prevented tumour progression in vivo .
In this study, increased loss of sIL-6R expression in colorectal
cancer was significantly correlated with well-known prognostic
Table 2 Multivariate analysis for predictors of survival in 161 colorectal cancer patients (a) and in UICC stage I, II, and III patients (b)
Univariate Multivariate
Variables HR 95% CI P-value HR 95% CI P-value
(a)
Gender (male vs female) 0.76 0.44–1.33 0.61
Age (o66 vs X66) 0.95 0.55–1.64 0.85
T classification (T1,2 vs T3,4) 0.21 0.08–0.52 0.0008* 0.56 0.20–1.55 0.27
Lymphatic vessel involvement (yes vs no) 2.08 0.65–6.667 0.22
Vessel involvement (yes vs no) 2.07 1.16–3.70 0.0141* 1.78 0.96–3.31 0.07
Node involvement (yes vs no) 2.34 1.33–4.13 0.0032* 1.02 0.54–1.91 0.96
Hepatic metastasis (yes vs no) 16.4 8.93–30.3 o0.0001* 12.3 6.25–24.4 o0.0001*
sIL-6R cancer/normal expression ratio (X1.0 vs o1.0) 0.35 0.19–0.63 0.0006* 0.38 0.20–0.72 0.0032*
(b)
Gender (male vs female) 1.15 0.36–2.07 0.75
Age (o66 vs X66) 0.86 0.37–1.99 0.73
T classification (T1,2 vs T3,4) 0.47 0.17–1.29 0.14 0.75 0.26–2.11 0.58
Lymphatic vessel involvement (yes vs no) 1.44 0.34–6.13 0.62
Vessel involvement (yes vs no) 2.44 0.99–6.02 0.05 2.7 1.07–6.85 0.0362*
Node involvement (yes vs no) 1.31 0.57–3004 0.53
sIL-6R cancer/normal expression ratio (X1.0 vs o1.0) 0.35 0.14–0.87 0.0230* 0.32 0.13–0.82 0.0169*
Abbreviations: CI¼confidence interval; HR¼hazard ratio; IL-6¼interleukin-6. *Po0.05.
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sfactors such as T classification, distant metastasis, and UICC
classification. Not only did all of the patients have significantly
poorer prognoses when the sIL-6R Cancer/N ratio was less than
1.0, but this effect was also enhanced in patients undergoing
surgery with curative intent. These data suggest that increased loss
of sIL-6R expression in colorectal cancer is deeply involved in
disease progression.
Interestingly, positive IL-6 immunohistochemical reactivity
in the cytoplasm of tumour cells was significantly associated
with reduced tumoral expression of sIL-6R. Interleukin-6 is
synthesised with a signal peptide, which generally leads to
co-translational transport into the endoplasmic reticulum which
may explain our immunohistochemical results that IL-6 mainly
exists in the cytoplasm of cancer cells. As IL-6 produced in cancer
cells can freely diffuse across the cell membrane into the stroma
(Miki et al, 2009), the loss of tumoral sIL-6R expression may reflect
either decreased production of sIL-6R itself or increased con-
sumption of sIL-6R by enhanced IL-6/sIL-6R affinity in the cancer
stroma. To clarify this hypothesis, we evaluated the kinetics of
sIL-6R production from tumour cells using an in vitro model.
Using semi-quantitative RT–PCR analysis, we found that IL-1b
stimulation appeared to increase the production of sIL-6R by both
enhanced shedding of the membrane-bound form of IL-6R, and
increased expression of the splice variant of IL-6R. Interestingly,
we also found that the addition of IL-1RA inhibited sIL-6R
production in a time-dependent manner. Interleukin-1RA is an
IL-1R antagonist that binds the same receptor on the cell surface as
IL-1, preventing IL-1 signalling. In a previous study, we found that
IL-1b stimulation induced IL-6 production in colorectal cancer
cells (Konishi et al, 2005), which was counteracted by IL-1RA,
suggesting that IL-1RA inhibits the IL-1/IL-6 cascade in colorectal
cancer cells. In this study, controlling the IL-1/IL-6 cascade using
IL-1RA decreased the production of sIL-6R. In addition, IL-1b
expression was positively associated with sIL-6R expression. These
data suggest that the IL-1–IL-6 cascade in cancer cells has a key
role in regulating the kinetics of sIL-6R in an autocrine fashion.
This inverse correlation between IL-6 and sIL-6R has been
reported in postoperative changes in serum concentrations under
intense surgical stress (Hatada and Miki, 2000; Wakuda et al,
2001).Wakuda et al (2001) showed the inversely serial change of
serum concentration of sIL-6R with IL-6 during the perioperative
period, and suggested that sIL-6R level was reduced by consump-
tion in the perioperative period . Recently, Egler et al (2008) have
shown that serum IL-6 levels were elevated in patients with high-
risk neuroblastoma, whereas sIL-6R levels followed an inverse
relationship with disease such that lower levels were present in
the patients with metastatic disease. These findings suggest that
decreased circulating levels of sIL-6R in aggressive malignant
disease reflect increased systemic IL-6 affinity for sIL-6R, resulting
in systemic consumption of sIL-6R. Interestingly, we also found
that the IL-1–IL-6 cascade in cancer cells regulated the kinetics
of soluble gp130 (sgp130). Soluble gp130 is the naturally occurring
antagonist of the interleukin-6 (IL-6)/sIL-6R complex, and
selectively inhibits IL-6 trans-signaling (Narazaki et al, 1993).
Although we could not determine why sIL-6R detection was
reduced by the concomitant enhanced expression of IL-6 in cancer
cells’ cytoplasm, it may be hypothesised that the increased release
of sIL-6R and sgp130 from cancer cells induced increased binding
of sIL-6R by both the soluble and membranous forms of gp130 in
cancer stroma, resulting in a decrease of sIL-6R in cancer tissue.
Obviously, the magnitude of immune cell infiltration might also
have an indispensable role in the complex interactions between
IL-6 and sIL-6R in cancer stroma, because IL-6, IL-1b, and in part
sIL-6R are produced by cancer cells, as well as by immune cells.
Thus, the increased binding of sIL-6R and the soluble and
membranous forms of gp130 arising from immune cells in cancer
stroma might also have roles in the decrease of sIL-6R in
cancer tissue.
In conclusion, loss of sIL-6R expression in colorectal cancer
is significantly correlated with disease progression. The intense
correlation between IL-6 expression in cancer cell and a decreased
sIL-6R Ca/N ratio may partly reflect exaggerated consumption of
sIL-6R by increased IL-6/sIL-6R affinity in the cancer stroma,
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Figure 3 (A–F) Typical examples of immunohistochemical staining
for IL-6 (A, D), membrane-associated IL-6R (B, E), and gp130 (C, F)i n
colorectal cancer (A, original magnification,  200; B, original magnifica-
tion,  200; C, original magnification,  200; D, original magnification,
 400; E, original magnification,  400; F, original magnification,  400).
(G) Kaplan–Meier curves of the actual 5-year survival rates of all patients,
segregated by high and low IL-6 expression in cancer cells’ cytoplasm.
(H, I) Typical examples of immunohistochemical staining of IL-6 at
different disease stages in colorectal cancer (H, early stage (UICC Stage I),
original magnification,  200; I, advanced stage (UICC Stage IV), original
magnification,  200).
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swhich maintains a favourable condition for tumour growth.
Recently, tocilizumab, a humanised anti-IL-6 receptor antibody,
has been used successfully in clinical trials in both adults and
Table 3a Relationship between IL-6, IL-6R and gp130 expressions in cancer cell/stroma and sIL-6R cancer/normal ratio
n sIL-6R cancer/normal ratio P-value n sIL-6R cancer/normal ratio P-value
IL-6 expression in cancer cell IL-6 expression in cancer stroma
+ 30 0.78±0.41 0.0015* + 3 0.63±0.47 0.19
  22 1.56±1.21   49 1.14±0.94
IL-6R expression in cancer cell IL-6R expression in cancer stroma
+ 13 1.10±0.83 0.68 + 1 1.595 0.22
  39 1.11±0.96   51 1.10±0.93
gp130 expression in cancer cell gp130 expression in cancer stroma
+ 6 0.98±0.52 0.93 + 2 0.69±0.13 0.51
  47 1.12±0.96   50 1.13±0.94
Abbreviations: IL-6¼interleukin-6; sIL-6R¼soluble form of interleukin-6 receptor. *Po0.05.
Table 3b Relationship between IL-6 expression in cancer cell/stroma and IL-6 cancer/normal ratio
n IL-6 cancer/normal ratio P-value n sIL-6R cancer/normal ratio P-value
IL-6 expression in cancer cell IL-6 expression in cancer stroma
+ 30 6.72±9.75 0.0288* + 3 6.28±9.38 0.79
  22 3.05±4.79   49 5.10±8.20
Abbreviations: IL-6¼interleukin-6; sIL-6R¼soluble form of interleukin-6 receptor. *Po0.05.
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Figure 4 (A) The HT-29 colon cancer cells express sIL-6R itself. sIL-6R secretion began 12h after incubation, and was increased by IL-1b stimulation.
IL-1RA suppressed the IL-1b-induced increase in sIL-6R secretion. (B) Although IL-6 expression was initially increased, the expression was gradually
downregulated in a time-dependent manner. (C) sgp130 expression was increased similar to sIL-6R expression in a time-dependent manner.
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Figure 5 Semi-quantitative RT–PCR analysis to detect both IL-6R
(398bp) and spliced sIL-6R, which lacks the transmembrane domain
(304bp), following cytokine stimulation. IL-1b stimulation enhances both
IL-6R splice variant expression and the shedding of the membrane-bound
form of IL-6R.
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Figure 6 Correlation between the sIL-6R Ca/N expression ratio and the
IL-1b Ca/N expression ratio. sIL-6R Ca/N expression ratio was positively
correlated with the IL-1b Ca/N expression ratio.
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schildren with rheumatological conditions, where IL-6 is known to
have a role (Plushner, 2008). In addition, eicosapentaenoic acid,
also known as an anti-inflammatory agent, was shown to stabilise
the IL-6 response. The therapeutic significance of the blockade of
IL-6 production or IL-6 signalling, which includes trans-signaling
through the IL-1–IL-6 cascade or sIL-6R, in the cancer micro-
environment remains to be clarified in future investigations. Our
data suggest that focusing on IL-6 trans-signaling may lead to new
therapeutic approaches to control tumour growth in colorectal
carcinomas.
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